Organization
University of Rochester Medical Center Department of Medical Oncology
4 abstracts
Abstract
BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.Org: ECOG-ACRIN Biostatistics Center, University Hospitals Seidman Cancer Center, University of Miami Sylvester Cancer Center, Ohio State University Comprehensive Cancer Center, Temple University Health System,
Abstract
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.Org: Mayo Clinic, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Rochester Medical Center Department of Medical Oncology, Loyola University Medical Center, Vanderbilt University Medical Center,
Abstract
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.Org: University of California San Diego Medical Center, La Jolla, CA, Wake Forest University School of Medicine, University of California San Francisco, University of Rochester Medical Center Department of Medical Oncology, University of Alabama at Birmingham Department of Hematology, Birmingham, AL,
Abstract
A pilot study of the combination of entinostat with capecitabine in high-risk breast cancer after neoadjuvant therapy.Org: University of Virginia Health System, University of Virginia, Charlottesville, VA, USA, James P. Wilmot Cancer Center/URMC - Pluta, University of Rochester Medical Center Department of Medical Oncology, VCU Department of Biostatistics,